Orforglipron
Cross-source consensus on Orforglipron from 1 sources and 5 claims.
1 sources · 5 claims
How it works
Benefits
Dosage & preparation
Preparation
Risks & contraindications
Highlighted claims
- Orforglipron is a once-daily nonpeptide oral GLP-1 receptor agonist being investigated for obesity and type 2 diabetes. — Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial
- Participants assigned to orforglipron began at 12 mg once daily and escalated every four weeks to 36 mg or their maximum tolerated dose. — Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial
- Orforglipron can be taken without restrictions on food or water intake. — Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial
- Orforglipron may reduce practical barriers associated with injectable incretin therapies. — Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial
- Direct transition to 12 mg orforglipron after injectable incretin therapy was generally well tolerated. — Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial